Castleark Management’s Standard BioTools LAB Stock Holding History

Castleark Management’s Portfolio LAB Stock Details LAB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q3	–	Sell	-273,077	Closed	-$3.36M	–	365
2019 Q2	$3.36M	Buy	273,077 +29,695	+12%	+$378K	0.13%	178
2019 Q1	$3.23M	Buy	+243,382	New	+$2.57M	0.12%	185

Other funds holding LAB

Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return

Neuberger Berman Group New York $131B AUM 28.36% 1-Year Est. Return

EIP

Easterly Investment Partners Beverly, Massachusetts $1.31B AUM 18.17% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Russell Investments Group London, United Kingdom $93.1B AUM 28.26% 1-Year Est. Return

PHS

PFM Health Sciences San Francisco, California $1.1B AUM 57.92% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

ICM

Indaba Capital Management San Francisco, California $33.8M AUM 33.83% 1-Year Est. Return

RTW Investments New York $10B AUM 135.35% 1-Year Est. Return

Castleark Management's LAB Position: Q3 2019 in Review

Castleark Management sold out of Standard BioTools (LAB) in Q3 2019, closing a stake of 273,077 shares — an estimated $3.36M sold.

Castleark Management first reported a position in LAB in Q1 2019 and held it in 2 quarters. The position peaked at $3.36M in Q2 2019. 125 funds tracked by Wall St. Rank hold LAB as of Q3 2019.

Castleark Management reported no remaining Standard BioTools position as of Q3 2019 after selling out during the quarter.
Castleark Management sold 273,077 Standard BioTools shares in Q3 2019, an estimated $3.36M.
Castleark Management first reported a position in Standard BioTools in Q1 2019 and held it in 2 quarters.
Castleark Management's Standard BioTools position peaked at $3.36M in Q2 2019.
125 funds tracked by Wall St. Rank held Standard BioTools as of Q3 2019.

Based on Castleark Management's 13F filing for Q3 2019, filed 15 Nov 2019.